AbbVie Highlights Blood Cancer Data From Its Growing Oncology Pipeline at the 64th ASH Annual Meeting

/PRNewswire/ -- AbbVie (NYSE: ABBV) will present results from nearly 65 company and partner abstracts across 8 types of cancer during the upcoming American...

Related Keywords

Canada ,Germany ,Louisiana ,United States ,New Orleans ,Belgium ,Italy ,France ,Spain ,Italian ,Belgian ,American ,German ,Acalabrutinib Monotherapy ,Gilteritinib Venetoclax ,Obinutuzumab Clb ,Mohamed Zaki ,Fludarabine Cytarabine Gemtuzumab Ozogamycin ,Epcoritamab Monotherapy ,Instagram ,Janssen Biotech Inc ,Genentech ,Linkedin ,Twitter ,Health Services ,American Society Of Hematology ,Facebook ,Health Authority ,Study Group ,Drug Administration ,Outcomes Research ,Youtube ,Health Care Resource Utilization ,Roche Group ,American Society Of Hemaotology ,Blood Cancer ,American Society ,Non Hodgkins Lymphomas ,Largeb Cell Lymphoma ,Follicular Lymphoma ,Chronic Lymphocytic Leukemia ,Small Lymphocytic Leukemia ,Acute Myeloid Leukemia ,Multiple Myeloma ,Line Ibrutinib ,Plus Venetoclax ,Versus Continued Ibr ,Median Follow Up ,Targeted Doublet Combinations ,Disease Dynamics Among Patients ,Fixed Duration Ibrutinib ,Targeted Doublet ,World Comparison ,Patients Initiated ,Single Agent Ibrutinib ,Lymphoid Malignancies ,Age Matched Population ,World Outcomes With First Line Ibrutinib ,Lymphocytic Leukemia ,Final Analysis ,Acalabrutinib Among Patients ,World Treatment Patterns ,Small Lymphocytic ,Switching From First Line Ibrutinib ,Plus Bendamustine Rituximab ,Versus Rituximab ,First Line Mantle Cell ,Mantle Cell ,Cell Lymphoma ,Score Measured ,Previously Treated ,Progressed Follicular Lymphoma ,Subgroup Results ,Real World Study ,Real Life Settings ,Observational Study ,World Outcome ,Italian Study ,Posteri Presentation ,Retention Rates ,Term Follow Up ,Venetoclax Plus Azacitidine ,Acute Myeloid Leukemia Ineligible ,Acute Myeloid Leukemias ,Commercially Available Therapies ,Venetoclax Plus Hypomethylating Agent Therapy ,Stratification Is Not Predictive ,Acute Myeloid ,Treatment Strategies ,Genetically Adverse Risk ,Omic Single Cell Sequencing Reveals Genetic ,Clonal Selection ,Molecular Pharmacology ,Drug Resistance ,Myeloid Neoplasms ,Antibody Therapeutic Targeting ,Newly Diagnosed ,Myeloid Leukemia ,Hypomethylating Agents ,Myeloid Malignancies ,Treatment Patterns ,Newly Diagnosed Older Adults ,Validated Composite Comorbidity ,Both Fitness ,Cytogenetic Risk ,Relapse Among Patients ,Venetoclax Based Treatment ,Real World Prospective Analysis ,World Effectiveness ,Data From The Observational Study ,Refractory Chronic ,Economic Impact ,Treatment Sequencing ,Real World ,Patient Preferences ,Updated Safety ,Efficacy Analysis ,Refractory Multiple ,Plasma Cell Dyscrasias ,Prospective Therapeutic Trials ,Response Analysis Supports ,Lower Dose ,Myeloma Patients When Combined ,Venetoclax Exposure ,Clinical Efficacy ,Biomarker Selected Patients ,Refractory Multiple Myeloma Receiving ,Real World Evaluation ,Sensitive Machine Learning Based Approach ,Emerging Tools ,Artificial Intelligence ,Genomic Analyses Demonstrate ,Myeloma Retainsb Cell Biology ,Myelodysplastic Syndromes ,Baseline Transfusion ,Randomized Phase ,Gemtuzumab Ozogamycin ,Relapsed Acute ,Investigational Therapies ,Excluding Transplantation ,Patients With Myelofibrosis Mediates ,Myeloproliferative Syndromes ,Latest Data ,Emerging Targeted Therapies ,Presentation Time ,Preclinical Models ,Subcutaneous Epcoritamab ,Patients With Relapsed ,Matureb Cell Neoplasms ,Aggressive Lymphomas ,Evaluate Safety ,Largeb Cell ,With Rituximab ,Care Resource Utilization ,Patients With Largeb Cell Lymphoma ,Lymphoma Treatment Patterns ,Real World Analysis ,Refractory Largeb Cell ,Novel Combinations ,Agents Among Patients ,Assessing Safety ,Refractory Diffuse Largeb Cell Lymphoma ,Autologous Stem Cell Transplant ,Immune Based ,Initial Results ,Peripheralt Cell Immune Profiling ,Refractory Non Hodgkin Lymphoma ,Baseline Samples ,World Outcomes ,Diffuse Largeb Cell Lymphoma Treated ,Cota Database ,Lymphoma Symptoms ,Largeb Cell Lymphoma Treated ,Including Minimal Residual Disease ,Novel Subgroup Analyses ,Yearly Results ,First In Human Phasei Study ,Drug Conjugate Composed ,Anti Cancer Regimens ,T Cell Redirecting Antibody ,Janssen Biotech ,Patient Information ,Blood Cancer Press ,Allergan Aesthetics ,Abbvie ,